

Amendments to the Claims:

This listing of claims will replace all prior versions and listings of the claims in the application:

Listing of Claims:

Claims 1-15 (Canceled herein).

16. An isolated polypeptide having at least 95% identity ~~along the full length of a second polypeptide, said second polypeptide having an amino acid sequence of any one of~~ to SEQ ID NOs 2, 10, ~~16 or 55~~, wherein said isolated polypeptide elicits ~~an~~ a protective antistreptococcal immune response in an individual when administered to the individual.

18. An isolated polypeptide having ~~an~~ the amino acid sequence of ~~any one of~~ SEQ ID NOs: 2, ~~10, 16 or 55~~.

19. (Original) An isolated polypeptide according to claim 18 wherein the N-terminal methionine residue of the polypeptide is deleted.

20. (Original). An isolated polypeptide according to claim 18, wherein the secretory amino acid sequence of the polypeptide is removed.

Claims 21-24 (Canceled herein).

25. A vaccine composition comprising a polypeptide having at least 95% identity ~~along the full length of a second polypeptide, said second polypeptide having an amino acid sequence of any one of~~ to SEQ ID NOs: 2, 10, ~~16 or 55~~, wherein said polypeptide elicits a protective antistreptococcal immune response in an individual when administered to the individual, and a pharmaceutically acceptable adjuvant.

Claims 26-32 (Canceled herein).

33. The vaccine composition of claim 25, said polypeptide having ~~an~~ the amino acid sequence of ~~any one of~~ SEQ ID NOs: 2, 10, 16 or 55.

34. (Original). The vaccine composition of claim 25, wherein the polypeptide lacks an N-terminal methionine residue.

35. (Original). The vaccine composition of claim 25, wherein the secretory amino acid sequence of the polypeptide is deleted.

Claims 36 and 37 (Previously canceled).

38 (Canceled herein).

39. (Previously added). The isolated polypeptide of claim 16, wherein the individual is a human, a mouse or a rat.

40. (Previously added). The vaccine composition of claim 25, wherein said adjuvant is selected from the group consisting of Freund's complete adjuvant, Freund's incomplete adjuvant, $\text{AlK}(\text{SO}_4)_2$, $\text{AlNa}(\text{SO}_4)_2$, $\text{AlNH}_4(\text{SO}_4)_2$, silica, kaolin, carbon polynucleotides, QuilA and Alhydrogel.

41. (Currently amended). The isolated polypeptide of claim 16, said polypeptide having at least a 99% identity ~~along the full length of said second polypeptide~~ to SEQ ID NO. 2.

42. (Previously added). The vaccine composition of claim 25, said polypeptide having at least a 99% identity ~~along the full length of said second polypeptide~~ to SEQ ID NO. 2.